Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Marko Kroselj"'
Autor:
Marko Krošelj, Petra Kolenc Peitl, Aljaž Sočan, Marijana Leskovec, Irena Mlinarič-Raščan, Tanja Gmeiner
Publikováno v:
Zdravniški Vestnik, Vol 87, Iss 9-10, Pp 439–452-439–452 (2018)
Nuklearna medicina pri obravnavi onkoloških bolnikov omogoča slikovni prikaz oziroma lokalizacijo tumorjev, ciljano zdravljenje ter spremljanje uspešnosti zdravljenja. Visoko specifične radiooznačene peptidne učinkovine lahko izkoristimo za cil
Externí odkaz:
https://doaj.org/article/633f3bf3b4be4869917ffada69c6f73f
Autor:
Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, Piotr Garnuszek
Publikováno v:
Pharmaceutics, Vol 15, Iss 3, p 885 (2023)
Broad availability and cost-effectiveness of 99Mo/99mTc generators worldwide support the use, and thus the development, of novel 99mTc-labelled radiopharmaceuticals. In recent years, preclinical and clinical developments for neuroendocrine neoplasms
Externí odkaz:
https://doaj.org/article/f1622523023c4c7a8174d282234f634f
Autor:
Alicja Hubalewska-Dydejczyk, Clemens Decristoforo, Petra Kolenc, Renata Mikolajczak, Luka Ležaić, Andrej Suden, Piotr Garnuszek, Urban Simoncic, Irene Virgolini, Malgorzata Trofimiuk-Muldner, Marta Opalinska, Christine Rangger, Boguslaw Glowa, Konrad Skorkiewicz, Melpomeni Fani, Staszczak Anna Sowa, Barbara Janota, Marko Kroselj, Katja Zaletel, Guggenberg Elisabeth Von
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76b478cab75f049c7c7afef8e7d0f85d
https://doi.org/10.1530/endoabs.90.p656
https://doi.org/10.1530/endoabs.90.p656
Autor:
Uroš Javornik, Marko Anderluh, Janez Plavec, Tihomir Tomašič, Petra Kolenc Peitl, Marko Kroselj, Doroteja Novak
Publikováno v:
ChemMedChem. 16:155-163
The cholecystokinin-2/gastrin receptor (CCK2 R) is considered a suitable target for the development of radiolabelled antagonists, due to its overexpression in various tumours, but no such compounds are available in clinical use. Therefore, we designe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b4c4f78197b3c0fa5b51c814874c608
https://doi.org/10.1002/cmdc.202000392
https://doi.org/10.1002/cmdc.202000392
Publikováno v:
Reference Module in Biomedical Sciences
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2c79f5d7af4b152ab9113c617f2a618
https://doi.org/10.1016/b978-0-12-822960-6.00041-7
https://doi.org/10.1016/b978-0-12-822960-6.00041-7
Autor:
Tanja Gmeiner, Milos Petrik, Aljaz Socan, Clemens Decristoforo, Christine Rangger, P. Kolenc Peitl, Marko Kroselj, U. Svajger, Zbynek Novy
Publikováno v:
Nuclear Medicine and Biology. 71:23-31
Introduction Indium-111 when formulated as indium-111 oxine remains the gold standard for long term cell tracking, whereas radiometals for improved PET applications still have to be established. We here describe the on-cartridge formation of gallium-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::562e7c52dbe5bb629152552986dbdbd7
https://doi.org/10.1016/j.nucmedbio.2019.04.001
https://doi.org/10.1016/j.nucmedbio.2019.04.001
Autor:
Marko Kroselj, Petra Kolenc Peitl, Tanja Gmeiner, Roger Knopp, Thorsten Dreger, Katja Zaletel, Aljaz Socan
Publikováno v:
Nuclear Medicine Communications. 37:207-214
OBJECTIVE With the vast development of theranostics and, recently, (68)Ga-radiolabeled molecules, there is also a need for novel, smaller, flexible, safe, and efficient modular automated synthesis systems in different clinical settings. The aim of ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db2a50c1f8cafff8403e1719ca337ecd
https://doi.org/10.1097/mnm.0000000000000411
https://doi.org/10.1097/mnm.0000000000000411
Autor:
Irena Mlinarič-Raščan, Tanja Gmeiner, Petra Kolenc Peitl, Marijana Leskovec, Aljaž Sočan, Marko Kroselj
Publikováno v:
Zdravniški Vestnik, Vol 87, Iss 9-10, Pp 439–452-439–452 (2018)
Nuklearna medicina pri obravnavi onkoloških bolnikov omogoča slikovni prikaz oziroma lokalizacijo tumorjev, ciljano zdravljenje ter spremljanje uspešnosti zdravljenja. Visoko specifične radiooznačene peptidne učinkovine lahko izkoristimo za cil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a863f9a56baae40d69578da2a0f5f7
https://doi.org/10.6016/zdravvestn.2634
https://doi.org/10.6016/zdravvestn.2634
Autor:
Renata Mikolajczak, Laura Ihli, Piotr Garnuszek, Clemens Decristoforo, Theodosia Maina, Leopold Kremser, Alicja Hubalewska-Dydejczyk, Paola Anna Erba, Michał Maurin, Dariusz Pawlak, Marko Kroselj, Petra Kolenc Peitl, Helmut R. Maecke, Christine Rangger
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Introduction A variety of radiolabelled minigastrin analogues targeting the cholecystokinin 2 (CCK2) receptor were developed and compared in a concerted preclinical testing to select the most promising radiotracer for diagnosis and treatment of medul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4920a5a3f7c45cab0a326c1209d4c3a
https://ruj.uj.edu.pl/xmlui/handle/item/94836
https://ruj.uj.edu.pl/xmlui/handle/item/94836
Autor:
Petra Kolenc Peitl, Rosalba Mansi, Helmut R. Maecke, Marko Kroselj, Marija Sollner Dolenc, Jean Claude Reubi, Maria-Luisa Tamma, Friederike Braun, Beatrice Waser
Publikováno v:
Bioconjugate chemistry. 26(6)
The metabolic instability and high kidney retention of minigastrin (MG) analogues hamper their suitability for use in peptide-receptor radionuclide therapy of CCK2/gastrin receptor-expressing tumors. High kidney retention has been related to N-termin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b606846e3bf6f6c00ccb59e49c067f7
https://pubmed.ncbi.nlm.nih.gov/25971921
https://pubmed.ncbi.nlm.nih.gov/25971921